Table 1.
Results of clinical trials of CAR-T Cells in Multiple Myeloma.
| Target antigen | Authors of the study | CAR | Number of patients | Conditioning therapy | Adverse events of CAR-T therapy | Effects of treatment |
|---|---|---|---|---|---|---|
| BCMA | Brudno (33) | CAR-T-BCMA | 16 | CXC 300 mg/m2 + FD 30 mg/m2 | * Severe CRS (2) * Hypotension (6) * Adrenal insufficiency (4) * Encephalopathy (1) * Pancytopenia (2) |
ORR 81% CR 13% VGPR 50% |
| BCMA | Raje (39) | B2121 | 33 | CXC 300 mg/m2 + FD 30 mg/m2 | * CRS (76%) * Neurologic toxicities (42%) |
ORR 85% CR 45% |
| BCMA | Bardeja (45) | B21217 | 22 | CXC 300 mg/m2 + FD 30 mg/m2 | * CRS (59%) * Neurotoxicity (23%) |
ORR 83% |
| BCMA | Zhao (46) | LCAR-B38M | 57 | CXC 300 mg/m2 | * Pyrexia (91%) * CRS (90%) * Thrombocytopenia (49%) * Leukopenia (47%) * Neurotoxicity (2%) * AST increased 39%) |
ORR 88% CR 68% VGPR 5% |
| BCMA | Madduri (48) | JNJ-4528 | 25 | CXC 300 mg/m2 + FD 30 mg/m2 | * CRS (88%) * Neutropenia (80%) * Anemia (76%) * Thrombocytopenia (72%) |
ORR 91%* CR 29% VGPR 33% |
| BCMA | Cohen (49) | CAR-T-BCMA (human scFv) |
25 | CXC 1,5 g/m2 or without conditioning | * CRS (88%) * Neurotoxicity (32%) |
Different ORR in 3 cohorts ranging 20-64% |
| BCMA | Mikkilineni (51) | FHVH-BCMA-T | 12 | CXC 300 mg/m2 + FD 30 mg/m2 | * CRS (92%) | ORR 83% CR 17% VGPR 25% |
| CD19 | Garfal (61) | CTL019+ASCT | 10 | MEL 140 mg/m2 or 200 mg/m2 | * CRS (10%) * Autologous GVHD (10%) * Most of AEs are due to high-dose melphalan |
ORR 80% |
*21 patients evaluable for response.
CAR, chimeric antigen receptor; BCMA, B-cell maturation antigen; CRS, cytokine release syndrome; CXC, cyclophosphamide; FD, fludarabine; MEL, melphalan, ORR, overall response rate; CR, complete remission; VGPR, very good partial remission; AST, aspartate aminotransferase; GVHD, graft-versus-host disease; AE, adverse events; FHVH, fully-human heavy-chain-only; ASCT, autologous stem-cell transplantation.